Immutep Ltd has released a press release.
Immutep Reports Positive Data from its TACTI-002 ph 2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- Immutep granted European patent for its LAG-3 candidate Efti
- Immutep enters New Collaboration with Merck KGaA for Efti
- Immutep granted Chinese patent for its LAG-3 candidate Efti
- Operational Update
- TACTI-002 & INSIGHT-004 data to be presented at ASCO
Later from Immutep
- Immutep Reveals a New anti-LAG-3 Research Program
- Immutep global webcast slides
- Immutep secures commitments for A$60 million in a Placement
- Efti to be evaluated in new triple combination therapy trial
- US FDA & IRB approves start of ph2b head & neck cancer trial
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep